AI Image
Eli Lilly puts up $100M for 5-target deal with China's InnoCare
fiercebiotech.com • • business
Key Points:
- Eli Lilly has committed $100 million upfront to InnoCare Pharma in a five-target drug discovery partnership, with potential milestones reaching up to $3.25 billion.
- The collaboration focuses on addressing critical unmet medical needs, though specific targets and therapeutic areas have not been disclosed.
- InnoCare will leverage its drug discovery platform and expertise in exchange for upfront fees, milestone payments, and tiered royalties based on product sales.
- Lilly continues its aggressive expansion strategy, fueled by GLP-1 product revenues, through high-value acquisitions and licensing deals this year.
- InnoCare, with a strong internal pipeline including VAV1 degrader and TYK2 inhibitor programs, remains selective in partnerships, emphasizing strategic globalization and financial stability.
